Quality Before Quantity?
The “$1.000 genome” is to my knowledge the buzzword everyone knows when thinking about Next Generation Sequencing.
And quite often I ask myself: What will be the future of NGS? Whole genome sequencing of everyone and everything?
I am confident that this is part of Illumina’s strategy for their new HiSeq X Ten instruments – at least for humans.
Contrary there is still all the data that needs to be analysed. And an interview with Lex Nederbragt highlights that data analysis is still a bottleneck. Also the latest report from Markets&Markets for whole exome sequencing predicts a strong growth in targetd sequencing. They estimate a growth for whole exome sequencing from $326.6 M in 2013 up to $884.1 Million by 2018.
So will quality, like sequencing distinct regions outcompete the $1,000 genome? What are your thoughts about that?